Key result
Analysis of 1,149,803 implantable defibrillators revealed highly significant differences in reliability between manufacturers, with 59.4% of malfunctions occurring in Abbott devices.
Why the study?
It was hypothesized that data in manufacturers' product performance reports can provide clinically valuable ICD and CRT-D reliability and longevity information.
Do reliability and battery longevity differ among ICD and CRT-D devices from different manufacturers?
Observational (n=1,149,803)
Do reliability and battery longevity differ among ICD and CRT-D devices from different manufacturers?
Significant differences exist in product reliability and battery longevity between ICD and CRT-D manufacturers, highlighting the value of analyzing product performance reports to inform device selection.
Answers are grounded in this paper and cite their sources.
Manufacturer differences in ICD reliability warrant caution in selection; leaves open need for prospective validation before guiding practice.
PURPOSE: We hypothesized that data in manufacturers' product performance reports (PPRs) can provide clinically valuable ICD and cardiac resynchronization defibrillator (CRT-D) reliability and longevity information. METHODS: Data were obtained from 2019 PPRs. Kaplan-Meier (K-M) probabilities of freedom from malfunction, normal battery depletion (NBD), and NBD + malfunction were calculated for ICD and CRT-D pulse generators (PGs) with LiMnO2 or LiSVO/CFx batteries marketed in the USA from 2010 to 2019 and compared using the log-rank test. Malfunctions (MAL) included PGs that were found outside specifications. RESULTS: Study population included 1,149,803 ICD and CRT-D PGs: Abbott (ABT; 35.1%), Biotronik (BIO; 4.6%), Boston Scientific (BSC; 23.5%), and Medtronic (MDT; 36.9%). Significant differences in reliability (p < 0.001), defined by freedom from MAL, were found between manufacturers; the majority of 6808 MAL occurred in ABT devices (n = 4045; 59.4%), followed by BSC (n = 2384; 35.0%), MDT (n = 338;5.0%), and BIO (n = 41; 0.6%). Battery failure (n = 890; 57.9%) was the most common cause of MAL compromising therapy; analysis of unique ABT battery MAL-indicated problem appeared a year prior to advisory. Significant differences (p < 0.001) in battery longevity, as defined by freedom from NBD, were found between manufacturers. Overall performance (freedom from NBD + MAL) favored BSC for CRT-D PGs and MDT and BIO for ICDs. BSC subcutaneous ICD reliability was inferior to its transvenous ICD (p < 0.001). CONCLUSION: PPRs contain valuable data that can be aggregated and analyzed to inform physicians. Differences in product reliability exist between manufacturers. Battery longevity has improved, but MAL have significantly impacted performance. PPR data may be useful for assessing product problems and new technology.
No takes yet. Share an insight, caveat, or question.
Hauser et al. (2021) conducted an observational in Patients requiring implantable cardioverter defibrillators (ICDs) and cardiac resynchronization defibrillators (CRT-Ds) (n=1,149,803). Implantable defibrillators (ICDs and CRT-Ds) vs. Comparison between manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic) was evaluated on Reliability (freedom from malfunction) and battery longevity (freedom from normal battery depletion) (p=<0.001). Analysis of 1,149,803 implantable defibrillators revealed highly significant differences in reliability between manufacturers, with 59.4% of malfunctions occurring in Abbott devices.
Synapse has enriched 10 related papers. Consider them for comparative context: